¡Nuestra primera publicación como grupo cooperativo! RENO Study: Clinical characteristics, treatment patterns and survival in RCC sciencedirect.com/science/articl…

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine nejm.org/doi/full/10.10…

Very proud to have led this 3 year investigation into future trends in prostate cancer globally. Out today in The Lancet Details below:

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment | Journal of Urology auajournals.org/doi/full/10.10…

FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma fda.gov/drugs/resource…

María Dolores Acón, galardonada en los Premios Sanitarias 2024 redaccionmedica.com/autonomias/can…

FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma fda.gov/drugs/resource…

From glioblastomas to sarcomas: genomic insights from 13,880 tumors showcases how specific genomic alterations could guide tailored #cancer treatments. #CancerGenomics #PrecisionMedicine #WGS nature.com/articles/s4159…

Ben Tran, MBBS, on Patterns of Relapse in Stage I Testicular Cancer medpagetoday.com/reading-room/a…

FDA Grants Breakthrough Therapy Designation to TAR-200 for BCG-Unresponsive High-Risk NMIBC onclive.com/view/fda-grant… via @onclive

El Clínic crea el Instituto del Cáncer para convertirse en un centro líder en oncología ⁦Hospital Clínic⁩ ⁦IDIBAPS⁩ ⁦Universitat de Barcelona⁩

#ClinicCCancerCenter lavanguardia.com/ciencia/202312…

International burden of cancer deaths and years of life lost from cancer attributable to four major risk factors: a population-based study in Brazil, Russia, India, China, South Africa, the United Kingdom, and United States - eClinicalMedicine thelancet.com/journals/eclin…

FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer fda.gov/drugs/resource…

FDA approves belzutifan for advanced renal cell carcinoma fda.gov/drugs/resource…

On the 🔝 with GUARD Consortium and #MAC (Mountainlife Against Cancer)
Daniel Castellano FLoscoMD Martín Angel Dr. Tomás Soulé Martin Richardet Mauricio Fernandez L Uromigos Toni Choueiri, MD Enrique Grande Javier Puente Javier Molina Cerrillo

Congrats Neeraj Agarwal, MD, FASCO on leading this wonderful work form the practice changing TALAPRO-2 trial in mCRPC! Impressive HRs!
Arun Azad Petros Grivas Sumanta K. Pal, MD, FASCO Neli Ulrich, PhD GU Cancer Research Program @HuntsmanCancer PCF Science

Pablo Iruzubieta: 'En los sistemas de oposición hacer un 'fellowship' no suma, te resta' diariomedico.com/medicina/medic… via @DiarioMedico

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma firstwordpharma.com/story/5806740?… via FirstWord Pharma

Evolving strategies in mHSPC
📌 Alberto Bossi Local treatment of the prostate in synchronous intensification #PROSCA23
Important messages (oligoM1):
- Translates in a 7% Overall Survival increase at 3 ys
- Defers the onset of Serious Local GU Events
- Delays the onset of the…

¡Solo quedan 2 semanas! No te pierdas nuestra Jornada de Acceso a Fármacos en tumores de la esfera GU este próximo 14 de diciembre en Barcelona. Mucho de lo que hablar y discutir, en un foro abierto y multidisciplinar. ¡Te esperamos!